STOCK TITAN
  1. Home
  2. Sec-filings
  3. DNA
  4. [8-K] Ginkgo Bioworks Holdings, Inc. Reports Material Event

Ginkgo Bioworks (NYSE: DNA) plans Q2 2026 results presentation and Q&A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. plans to host a presentation and Q&A session reviewing its business performance for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, beginning at 4:30 p.m. ET.

The session will be webcast via Ginkgo's investor relations website, with a replay available. Shareholders may submit questions in advance via X to @Ginkgo using hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com. The company highlights its websites, blog, news site, and social media channels as outlets for potentially material information.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 presentation date August 5, 2026 Scheduled date for reviewing business performance for the second quarter ended June 30, 2026
Presentation start time 4:30 p.m. ET Start time for Ginkgo's Q2 2026 business performance presentation and Q&A session
Quarter end date June 30, 2026 End date of the second quarter to be discussed in the August 5, 2026 presentation
Exhibit 99.1 Announcement, issued by Ginkgo Bioworks Holdings, Inc. on July 30, 2026 Exhibit describing the planned Q2 2026 results presentation and Q&A
Exhibit 104 Cover Page Interactive Data File Inline XBRL cover page data file embedded within the filing
Regulation FD Disclosure regulatory
"Item 7.01. Regulation FD Disclosure describes the planned presentation."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
Inline XBRL regulatory
"Cover Page Interactive Data File (embedded within the Inline XBRL)."
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
cloud lab technical
"In-house autonomous lab is also available as a cloud lab offering."
A cloud lab is a remotely operated laboratory where automated instruments and robotic systems run experiments on behalf of users who send protocols over the internet. For investors it matters because companies can outsource costly equipment and staff, scale research faster, and reduce the risk that a single lab breakdown will stall product development—similar to renting a shared, online factory instead of building your own.
contract research services technical
"Available as a cloud lab through Datapoints and Solutions contract research services."
autonomous laboratories technical
"The company offers autonomous laboratories that replace manual laboratory work with robotics."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

When will Ginkgo Bioworks (DNA) hold its Q2 2026 results presentation?
Ginkgo Bioworks will hold its Q2 2026 business performance presentation on Wednesday, August 5, 2026, at 4:30 p.m. ET. The event will review results for the quarter ended June 30, 2026, and include a Q&A session with participants.

How can Ginkgo Bioworks (DNA) investors access the Q2 2026 webcast and replay?
Investors can access the Q2 2026 presentation via a webcast link on Ginkgo's investor relations website. A replay will also be available at the same link, allowing shareholders to review the discussion after the live session concludes.

How can shareholders submit questions for Ginkgo Bioworks (DNA) Q2 2026 session?
Shareholders can submit questions in advance by sending them to @Ginkgo on X with hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com. These channels are available before the August 5, 2026 presentation and Q&A session.

What period will Ginkgo Bioworks (DNA) discuss during the August 5, 2026 presentation?
The presentation will cover Ginkgo Bioworks' business performance for the second quarter ended June 30, 2026. Management plans to review results for this period and address questions from investors during the scheduled Q&A session.

Which channels does Ginkgo Bioworks (DNA) use to share material information?
Ginkgo Bioworks uses SEC filings, public conference calls, its corporate and investor websites, its news site, blog, and social media on X, Instagram, Threads, and LinkedIn to communicate information that could be considered material to investors.
0001830214FALSE00018302142026-07-302026-07-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________
FORM 8-K
______________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 30, 2026
______________________________________________________________
GINKGO BIOWORKS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
______________________________________________________________
Delaware001-4009787-2652913
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
27 Drydock Avenue
8th Floor
Boston, MA 02210
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (877) 422-5362
(Former name or former address, if changed since last report)
______________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act
Title of each classTrading
Symbol(s)		Name of each exchange
on which registered
Class A common stock, par value $0.0001 per shareDNANYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 7.01. Regulation FD Disclosure.

Ginkgo Bioworks Holdings, Inc. (the “Company”) announced today that it plans to host a presentation and Q&A session reviewing its business performance for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, beginning at 4:30 p.m. ET.

The presentation details and webcast link will be available on Ginkgo’s investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available at the same link following the session. Shareholders may ask a question ahead of the presentation by submitting them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations website (https://investors.ginkgobioworks.com) and its news site (https://investors.ginkgobioworks.com/news). Ginkgo uses these channels, as well as its blog (https://www.ginkgo.bio/resources) and social media accounts on X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) and LinkedIn to communicate with investors and the public about the Company and other matters and encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.

Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
Exhibit
Number		Description
99.1
Announcement, issued by Ginkgo Bioworks Holdings, Inc. on July 30, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GINKGO BIOWORKS HOLDINGS, INC.
Date: July 30, 2026By:/s/ Steven Coen
Name:Steven Coen
Title:Chief Financial Officer


Ginkgo Bioworks Announces Date of Second Quarter 2026 Results Presentation
Presentation and Q&A session scheduled for post-market on Wednesday, August 5, 2026
BOSTON – July 30, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, beginning at 4:30 p.m. ET.
The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.
To ask a question ahead of the presentation, please submit them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo’s in-house autonomous lab is also available as a “cloud lab” through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations website (https://investors.ginkgobioworks.com) and its news site (https://investors.ginkgobioworks.com/news). Ginkgo uses these channels, as well as its blog (https://www.ginkgo.bio/resources) and social media accounts on X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) and LinkedIn to communicate with investors and the public about the Company and other matters and encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.

Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com


MEDIA CONTACT:
press@ginkgobioworks.com

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents